Companies: 10,795·Total market cap: $144.5T
Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd.

KNSANASDAQHealthcare● Active
$48.49
+$0.07(+0.14%)
Market Cap$3.6B
P/E Ratio—
52W High$59.87
52W Low$26.27
SEC Filings

Kiniksa Pharmaceuticals, Ltd. (KNSA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001730430 · KNSA · NASDAQ · as of Jun 8, 2026

Filing snapshot

746
Total Filings
4
Latest Form
2026-06-02
Most Recent
2018
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001730430 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-24
Fiscal Year End
Feb 24, 2026
Accession No.
0001104659-26-019168
Primary Document
knsa-20251231x10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001730430 · Accession 0001104659-26-019168

Latest Key Filings

10-QQuarterly Report
10-Q
2026-04-28
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-29Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-05-29
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-26
View
8-KCurrent Report
8-K
2026-05-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-06
View
8-KCurrent Report
8-K
2026-05-01
View
10-QQuarterly Report
10-Q
2026-04-28
View
8-KCurrent Report
8-K
2026-04-28
View
ARSARS
ARS
2026-04-16
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-16
View
DEF 14AProxy Statement
DEF 14A
2026-04-16
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-27
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-03-06
View
S-8Employee Stock Plan Registration
FORM S-8
2026-02-24
View
10-KAnnual Report
10-K
2026-02-24
View
8-KCurrent Report
8-K
2026-02-24
View
Showing 1–15 of 318 filingsForm 4 / 144 hidden· 746 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001730430  |  Exchange: NASDAQ · Healthcare

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) has submitted 746 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001730430, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Kiniksa Pharmaceuticals, Ltd.'s most comprehensive regulatory disclosure. The most recent Kiniksa Pharmaceuticals, Ltd. 10-K was filed on 2026-02-24 for fiscal year ending 2026. Historical KNSA 10-K annual reports are available from 2018 through 2026.

Investors researching Kiniksa Pharmaceuticals, Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
CDTX SEC Filings →APLS SEC Filings →SRRK SEC Filings →FOLD SEC Filings →CPRX SEC Filings →VCYT SEC Filings →IDYA SEC Filings →ADPT SEC Filings →
→ KNSA Financials→ KNSA Earnings→ KNSA Insider Trades

Frequently Asked Questions

KNSA SEC Filings · 8 questions

Kiniksa Pharmaceuticals, Ltd. (KNSA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 746 filings and access original documents at no cost. Kiniksa Pharmaceuticals, Ltd.'s CIK is 0001730430.

KNSA SEC filingsKiniksa Pharmaceuticals, Ltd. SEC documentsfind KNSA 10-K